https://orcid.org/0000-0001-5144-4021
References
- Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1315.
- Bharucha AE, Dunivan G, Goode PS, et al. Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol. 2015;110(1):127–136.
- Mandimika CL, Murk W, Mühlhäuser McPencow A, et al. Knowledge of pelvic floor disorders in a population of community-dwelling women. Am J Obstet Gynecol. 2014;210(2):165.e1–165.e9.
- Wong JW, Kaneshiro BE, Oyama IA. Primary care physician perceptions of female pelvic floor disorders. Hawaii J Med Public Health. 2019;78(4):132–136.
- Meyer I, Richter HE. Impact of fecal incontinence and its treatment on quality of life in women. Womens Health. 2015;11(2):225–238.
- Brown HW, Guan W, Schmuhl NB, et al. If we don’t ask, they won’t tell: screening for urinary and fecal incontinence by primary care providers. J Am Board Fam Med. 2018;31(5):774–782.
- Krissi H, Eitan R, Edward R, et al. Diagnostic delay in secondary care for lower urinary tract and pelvic organ prolapse symptoms in women. Arch Gynecol Obstet. 2012;286(1):115–118.
- Mazloomdoost D, Crisp CC, Kleeman SD, et al. Primary care providers’ experience, management, and referral patterns regarding pelvic floor disorders: a national survey. Int Urogynecol J. 2018;29(1):109–118.
- Ghijselings L, Van De Putte D, Hervé F, et al. The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium. Acta Clin Belgica Int J Clin Lab Med. 2019;1–6. DOI https://doi.org/10.1080/17843286.2019.1630109
- Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3)558–563.
- Goldman HB, Lloyd JC, Noblett KL, et al. International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn. 2018;37(5):1823–1848.
- Mahieu T, Miermans P, Horn M, et al. Federal public service, health, food chain safety and environment. Brussels: Tom Auwers; 2018. Available from: https://overlegorganen.gezondheid.belgie.be/sites/default/files/documents/statan_2018_nl_1.pdf
- Kunduru L, Kim SM, Heymen S, et al. Factors that affect consultation and screening for fecal incontinence. Clin Gastroenterol Hepatol. 2015;13(4):709–716.
- Amundsen CL, Richter HE, Menefee S, et al. The refractory overactive bladder: sacral neuromodulation vs. botulinum toxin assessment: ROSETTA trial. Contemp Clin Trials. 2014;37(2):272–283.
- Imam KA. The role of the primary care physician in the management of bladder dysfunction. Rev Urol. 2004;6(1):S38–S44.